Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 32: | Line 32: | ||
===Current Modifications=== | ===Current Modifications=== | ||
* In addition to family history, overweight and obesity should trigger screening with a fasting lipid profile. | * In addition to family history, overweight and obesity should trigger screening with a fasting lipid profile. | ||
* Overweight and obese children with lipid abnormalities should be screened for other aspects of the metabolic syndrome (i.e., insulin resistance and type 2 diabetes, hypertension, or central adiposity). | * Overweight and obese children with lipid abnormalities should be screened for other aspects of the metabolic syndrome (i.e., insulin resistance and type 2 diabetes, hypertension, or central adiposity). | ||
Line 46: | Line 45: | ||
** Presence of novel and emerging risk factors and markers, e.g., elevated lipoprotein(a), homocysteine, C-reactive protein | ** Presence of novel and emerging risk factors and markers, e.g., elevated lipoprotein(a), homocysteine, C-reactive protein | ||
* Ongoing research of drug therapy of high-risk lipid abnormalities in children is needed, particularly with regard to long-term efficacy and safety, and impact on the atherosclerotic disease process. | * Ongoing research of drug therapy of high-risk lipid abnormalities in children is needed, particularly with regard to long-term efficacy and safety, and impact on the atherosclerotic disease process. | ||
}} | }} | ||
Revision as of 14:08, 29 October 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information click here
Template:DiseaseDisorder infobox
WikiDoc Resources for Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
|
Guidelines / Policies / Govt |
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Children and adolescents with high-risk hyperlipidemia require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia, despite compliance with lifestyle recommendations .
NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents
Original Recommendations of the National Cholesterol Education Program (NCEP) Expert Panel for Drug Therapy of High-Risk Hyperlipidemia in Children and Adolescents [1] (DONOT EDIT)
“ |
Current Modifications
|
” |
References
- ↑ McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP; et al. (2007). "Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing". Circulation. 115 (14): 1948–67. doi:10.1161/CIRCULATIONAHA.107.181946. PMID 17377073.